A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapyChristoph K. Stein‐Thoeringer, Eran Elinav, Roman Rohrbach et al.|Nature Medicine|2023Cited by 226
XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myelomaJoel G. Turner, Daniel M. Sullivan|Oncotarget|2016Cited by 89
Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitorsJoel G. Turner, Daniel M. Sullivan|Journal of Hematology & Oncology|2016Cited by 84
CRM1 Inhibition Sensitizes Drug Resistant Human Myeloma Cells to Topoisomerase II and Proteasome Inhibitors both In Vitro and Ex VivoJoel G. Turner, Daniel M. Sullivan|Journal of Cancer|2013Cited by 78
Melphalan and Exportin 1 Inhibitors Exert Synergistic Antitumor Effects in Preclinical Models of Human Multiple MyelomaJoel G. Turner, Daniel M. Sullivan|Cancer Research|2020Cited by 21